Recently, Marshall et al. [36], in order to value EGFR expression as a target in osteosarcoma, designed a complex nanoparticle that was able to deliver doxorubicin (a DNA-damaging agent) using a conjugated EGFR antibody. The gene discussed is EGFR; the disease is osteosarcoma.